Literature DB >> 9314292

Conceptual basis for advances in the systemic drug therapy of breast cancer.

L Norton1.   

Abstract

Several directions are currently being explored to improve treatment outcome among patients with breast cancer. Although regulation of cell division likely will be necessary to effect an ultimate cure for cancer, work continues into maximizing responses to chemotherapy to manage the neoplastic progression and symptoms of disease. While new anticancer agents are being sought, progress has been most readily achieved through the concepts of drug dosing and scheduling. Manipulating treatment impact by altering drug intensity and using novel scheduling strategies are yielding improvement in responses, and newer concepts, such as the limits of cytoreduction, are gaining prominence in clinical trials. This article reviews the current knowledge, ongoing research protocols, and future directions in these areas of systemic therapy for breast cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9314292

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  3 in total

1.  Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma.

Authors:  P M Dodd; J A McCaffrey; M Mazumdar; E Icasiano; G Higgins; H Herr; D F Bajorin
Journal:  Invest New Drugs       Date:  2000-08       Impact factor: 3.850

2.  Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium.

Authors:  Matthew I Milowsky; David M Nanus; Fernando C Maluf; Svetlana Mironov; Weiji Shi; Alexia Iasonos; Jamie Riches; Ashley Regazzi; Dean F Bajorin
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

Review 3.  SABCS 2017: update on chemotherapy, targeted therapy, and immunotherapy.

Authors:  Rupert Bartsch; Elisabeth Bergen
Journal:  Memo       Date:  2018-08-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.